InVivo Therapeutics Announces Publication of 12- and 24-month Data for INSPIRE 1.0 Study in Peer-Reviewed Neurosurgery

Manuscript particulars affected person outcomes by 24-month comply with up go to

June 8, 2022

CAMBRIDGE, Mass.–(BUSINESS WIRE)–InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV) at present introduced the publication of a peer-reviewed manuscript in Neurosurgery describing the beforehand disclosed 12- and 24-month knowledge from the Firm’s single-arm INSPIRE 1.0 Examine (InVivo Examine of Possible Good thing about the Neuro-Spinal Scaffold™ for Security and Neurologic Restoration in Topics with Full Thoracic AIS A Spinal Cord Injury). The publication is titled “Acute Implantation of a Bioresorbable Polymer Scaffold in Sufferers with Full Thoracic Spinal Cord Injury: 24-Month Observe-up from the INSPIRE Examine.”

Richard Toselli, M.D., InVivo’s President and Chief Govt Officer, mentioned, “Along with the earlier six-month publication overlaying INSPIRE 1.0 knowledge within the Journal of Neurosurgery: Backbone, we’re happy to see the analysis of affected person outcomes by the 24-month comply with up go to. We’re inspired that these knowledge assist additional analysis of the investigational Neuro-Spinal Scaffold™ and its potential profit to sufferers within the ongoing INSPIRE 2.0 Examine.”

InVivo has formally closed the INSPIRE 1.0 research and just lately accomplished enrollment right into a second pivotal scientific research of the investigational Neuro-Spinal Scaffold™ in sufferers with acute SCI (INSPIRE 2.0). InVivo anticipates presenting topline knowledge from the INSPIRE 2.0 Examine in first quarter of 2023. The INSPIRE 2.0 research is a 20-patient (10 topics in every research arm), randomized, managed trial that’s designed to reinforce the prevailing scientific proof for the Neuro-Spinal Scaffold™ from the INSPIRE 1.0 research. For extra details about the INSPIRE 2.0 scientific trial, please go to ClinicalTrials.gov.

The publication is now out there electronically at this hyperlink.

About InVivo Therapeutics

InVivo Therapeutics Holdings Corp. is a analysis and clinical-stage biomaterials and biotechnology firm with a give attention to remedy of spinal twine accidents. The corporate was based in 2005 with proprietary know-how co-invented by Robert Langer, Sc.D., Professor at Massachusetts Institute of Expertise, and Joseph P. Vacanti, M.D., who then was at Boston Youngsters’s Hospital and who now’s affiliated with Massachusetts Common Hospital. The publicly traded firm is headquartered in Cambridge, MA. For extra particulars, go to www.invivotherapeutics.com.

Protected Harbor Assertion

Any statements contained on this press launch that don’t describe historic details might represent forward-looking statements inside the that means of the federal securities legal guidelines. These statements could be recognized by phrases corresponding to “consider,” “anticipate,” “intend,” “estimate,” “will,” “might,” “ought to,” “anticipate” and comparable expressions, and embody statements relating to the corporate’s expectation relating to the timing for the announcement of topline knowledge and skill to serve the spinal twine harm affected person inhabitants. Any forward-looking statements contained herein are based mostly on present expectations and are topic to a lot of dangers and uncertainties. Components that would trigger precise future outcomes to vary materially from present expectations embody, however usually are not restricted to, dangers and uncertainties referring to: the corporate’s means to acquire extra funding to assist the continued scientific and potential commercialization program for the investigational Neuro-Spinal Scaffold™, the various interpretation of scientific knowledge, the timing, value and expense of regulatory filings, the potential for regulatory authorities granting or delaying approval for our Neuro-Spinal Scaffold, and different dangers related to the corporate’s enterprise, analysis, product improvement, regulatory approval, advertising and marketing and distribution plans and techniques recognized and described in additional element within the firm’s Quarterly Report on Type 10-Q for the quarter ended March 31, 2022, and in different filings that the corporate might make with the Securities and Alternate Fee sooner or later. The corporate doesn’t undertake to replace these forward-looking statements.